Medico Remedies Share Price

Medico Remedies Limited, with its corporate operations in Mumbai, functions as a pharmaceutical formulation manufacturing company in India. The company was incorporated in 1994. Medico Remedies develops, manufactures, and sells pharmaceutical and nutraceutical products, focusing on anti-infectives, beta-lactams (penicillins and cephalosporins), antimalarials, antiretrovirals, anti-ulcer drugs, antacids, vitamins, haematinics, and other supplements. The company serves domestic and export markets in Latin America, Southeast Asia, and Africa through its product portfolio of tablets, capsules, ointments, creams, and syrups. 

Medico Remedies share price on NSE and BSE signifies how market participants react to the company’s operational performance and the overall developments in the pharmaceutical sector. The company’s financial health depends on production volumes of pharmaceutical formulations, raw material costs including active pharmaceutical ingredients (APIs), capacity utilization rates, domestic and export demand, and the performance of its contract manufacturing and branded product segments. Medico Remedies stock price is influenced by various factors such as earnings, regulatory approvals from health authorities, changes in drug manufacturing standards, and competition from generic drug players. In the longer run, strategies such as new product launches, capacity expansion, and entry into new markets affect the stock market sentiments. All these factors need to be monitored closely to have an idea about the company’s stock price movements. 

Medico Remedies live share price provides real-time information about the last price traded, bid and ask prices, and volume traded. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the Medico Remedies live price helps in observing short term price volatility and shows how a stock moves relative to the broader healthcare index. Furthermore, monitoring Medico Remedies stock price movements helps investors understand real-time market sentiment, price fluctuations, and trading behaviour. It allows them to evaluate short-term performance, and respond to news, quarterly results, or sector trends that may influence the company’s valuation and overall investment outlook. 

Medico Remedies Limited Company Fundamentals 

a. Company Background 

Medico Remedies Limited was incorporated in 1994 and is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company operates primarily in the pharmaceutical formulation segment, supplying products such as antibiotics, anti-infectives, cardiovascular drugs, anti-diabetics, anti-inflammatory drugs, and nutritional supplements. Its manufacturing operations are based in India, with a major production facility located in the Palghar district of Maharashtra. Over time, the company has expanded its product portfolio and export presence to Latin America, Southeast Asia, and Africa. 

Medico Remedies stock is traded on both major Indian exchanges. The company maintains a debt-free balance sheet with zero promoter pledges, providing financial stability. Market valuation indicators are used by analysts for comparative assessment within the pharmaceutical manufacturing sector. Overall fundamentals are influenced by raw material availability, demand cycles across therapeutic segments, and input cost fluctuations. 

b. Company Product Lines 

• Antibiotics and anti-infectives including beta-lactams (penicillins and cephalosporins) 

• Antifungals, anti-malarials, anti-retrovirals, and anti-ulcer drugs 

• Cardiovascular products, anti-diabetics, and non-steroidal anti-inflammatory drugs 

• Vitamins and dietary supplements, haematinics, and other nutraceutical products 

• Antidepressants, antipsychotics, anti-epileptics, and anti-histaminic drugs 

• Diuretics, steroidal preparations, ointments, creams, syrups, and dry powder for suspensions 

• The company also manufactures tablets, capsules, and liquid orals in various dosage forms 

c. Company Revenue Model 

• Domestic sales of pharmaceutical formulations to distributors, hospitals, and retail pharmacies across India 

• Export sales to international customers in Latin America, Southeast Asia, and African countries 

• Contract manufacturing for other pharmaceutical companies who market products under their own brand names 

• Institutional contracts with government healthcare facilities and tenders from state health departments 

• Revenue performance is primarily influenced by demand for pharmaceutical products, raw material costs (especially active pharmaceutical ingredients), and selling price realizations in domestic and export markets 

d. Geographic Presence 

• Corporate headquarters located in Mumbai, Maharashtra, India 

• Manufacturing facility in the Palghar district of Maharashtra 

• Domestic distribution network across India through pharmaceutical distributors, hospital supply channels, and medical stores 

• Export markets include Latin American countries, Southeast Asian nations, and various African countries serving international pharmaceutical buyers 

• Clients include Indian as well as foreign pharmaceutical companies such as Anphar Limited, Saad Medical, Manfes Pharmaceuticals & Chemical Industries, and others 

e. Key Milestones 

• 1994: Incorporation of Medico Remedies Limited 

• 2018: Initial Public Offering (IPO) listing on NSE and BSE on 8th February 2018 at an issue price of Rs 100 per share 

• Recent years: Completion of ISO certifications, development of new product pipeline, and commencement of work for a new manufacturing facility for B-lactum tablets, capsules, dry syrup, and injections 

• Ongoing: Continued focus on expanding export footprint and product portfolio diversification 

f. Industry Perspective 

The pharmaceutical formulation manufacturing industry is capital-intensive and closely linked to demand from healthcare, hospitals, and retail sectors. Demand trends are influenced by economic activity, disease prevalence patterns, government health policies, and growth in health insurance coverage. 

The industry is also affected by fluctuations in raw material prices such as APIs and excipients, along with energy and logistics costs. Environmental regulations and good manufacturing practices compliance requirements are increasingly shaping production practices and capital investment decisions. Companies in the sector must manage competitive pressures, regulatory approvals, and price control mechanisms while maintaining operational efficiency. These factors collectively influence financial performance and investor perception of firms like Medico Remedies. 

Medico Remedies Limited Stock Market Presence: Listings & Index Representation 

Medico Remedies Limited is listed on the National Stock Exchange (NSE) under the symbol MEDICO and on the Bombay Stock Exchange (BSE) with the scrip code 540937. Medico Remedies share price is actively traded on both exchanges. The company’s market presence is within the small-cap segment of the market. Due to its size and sector focus, Medico Remedies stock price is generally tracked by investors interested in the pharmaceutical and healthcare industry. 

Medico Remedies Limited is part of several broad-based and sector-specific stock market indices, reflecting its position as a small-cap pharmaceutical company in India. While it is not included in benchmark indices like the Sensex or Nifty 50, it is a constituent of wider market indices such as the BSE SmallCap and BSE Healthcare indices. Medico Remedies share price finds representation in these indices based on its market standing. This presence helps investors track the stock relative to other pharmaceutical formulation manufacturing companies. 

Medico Remedies Limited Stock Performance and Share Price History 

Medico Remedies share price on NSE reflects its status as a pharmaceutical formulation manufacturer in India. Performance is driven by production capacity utilization, raw material cost management, domestic distribution reach, and the company’s ability to manage operational expenses. Investors compare Medico Remedies share price today with other pharmaceutical manufacturers and generic drug producers to gauge relative performance. 

These underlying factors are often visible through real market movements across different periods. Similar trends are observed during earnings-driven movements. Broader sector strength has also played a role in supporting Medico Remedies share price. In addition to operational and sector-led factors, corporate actions such as the company’s initial public offering in 2018 have shaped the company’s capital structure over the long term. This shows how corporate actions can have lasting impacts on the company’s financial positioning, even within a regulated pharmaceutical framework influenced by drug pricing policies and regulatory compliance. 

While short-term movements reflect events and announcements, longer-term valuation trends are visible through Medico Remedies share price 52-week high and low, providing context beyond daily or weekly changes. Based on available data, the stock’s 52-week high stood at approximately 62.48, while the 52-week low stood at approximately 37.18. Highs suggest stronger pharmaceutical demand and stable margins, while lows align with market corrections or sector volatility. These levels capture impacts of pharmaceutical policies, global generic drug trends, and earnings visibility, providing context for the stock’s historical performance. 

Medico Remedies’s stock performance reflects the trading behaviour of a small-cap pharmaceutical company operating within India’s drug manufacturing ecosystem. The company’s diversified portfolio across antibiotic, anti-infective, and nutraceutical products has shaped its Medico Remedies share price history. Over the past five years, the stock has shown periods of sharp gains and phases of consolidation. The stock delivered a positive annual return of approximately 28.6 percent in 2020, while recording negative returns in 2025 of approximately 11.4 percent and 2024 of approximately 34.3 percent. The stock underperformed the BSE Healthcare index over the one-year, three-year, and five-year periods, with a three-year return of negative 18.4 percent compared to the BSE Healthcare index which delivered positive 25.3 percent over the same period. The stock’s financial year 2025 return was negative 11.4 percent. From recent periods onwards, the Medico Remedies share price has shown a year-to-date negative return of approximately 21.6 percent and a one-month return of negative 15.7 percent. The beta of the stock stands at approximately 0.09, indicating very low volatility compared to the broader market. 

Medico Remedies’s stock performance over time has closely followed India’s pharmaceutical demand and global generic drug cycles. The Medico Remedies share price showed positive momentum in 2020 with a return of 28.6 percent, reflecting the post-pandemic recovery and increased demand for pharmaceutical products. However, periods of high raw material costs and competitive pressures have contributed to consolidation in Medico Remedies stock price. The company’s profit after tax increased by approximately 21.71 percent year-on-year in FY 2024-25, primarily due to higher sales realization and improved operational efficiency. The company’s revenue grew from approximately 140.44 crore rupees in FY 2023 to approximately 150.94 crore rupees in FY 2025, while profit after tax increased from approximately 7.24 crore rupees to approximately 10.09 crore rupees over the same period. These returns highlight the cyclical and competitive nature of the pharmaceutical industry. 

Despite COVID-19 disruptions, Medico Remedies shares showed resilience during the pandemic period, with the company benefiting from sustained demand for essential pharmaceutical products. While the broader pharmaceutical sector faced challenges with supply chain disruptions and logistics, the company’s diversified product portfolio across anti-infectives, vitamins, and nutraceuticals helped the stock retain value. The company has over 213 employees and exports to international markets. The company has also undertaken capacity expansion, commencing work for a new factory for manufacturing of B-lactum tablets, capsules, dry syrup, and injections, to meet future demand. 

Medico Remedies share price has seen decreases due to several recurring reasons. A decline in export demand or a drop in formulation realizations directly impacts profitability and leads to selling pressure. Changes in government policy, such as stricter environmental regulations for pharmaceutical manufacturing or changes in drug price controls under the National Pharmaceutical Pricing Authority, can also cause the stock to fall. Furthermore, any increase in operational costs like raw material procurement or energy expenses without a matching rise in product prices squeezes the company’s margins, making the stock less attractive. Periods of global economic slowdown that affect pharmaceutical spending raise concerns about export volumes, leading to a drop in Medico Remedies share price. The stock is also sensitive to raw material price movements; if API prices rise significantly affecting input costs, it can lead to a decrease in Medico Remedies stock price as investors adjust expectations for future margin growth. Broader market sell-offs in small-cap stocks also pull the price down, regardless of the company’s individual performance. A decrease in capacity utilization or lower sales in any product category directly hurts the company’s revenue, resulting in a lower valuation for Medico Remedies share price. The stock underperformed the BSE Healthcare index by a significant margin over the one-year period, with the company reporting a one-year return of negative 29.36 percent compared to the BSE Healthcare index return of approximately 7.7 percent. 

Medico Remedies Limited Investor Relevance and Role in Portfolio 

Medico Remedies Limited is a holding in small-cap and pharmaceutical portfolios, offering exposure to antibiotic, anti-infective, and nutraceutical manufacturing. Inclusion in healthcare indices underscores its importance in India’s generic pharmaceutical manufacturing space. The company’s debt-free balance sheet, zero promoter pledges, and diversified product portfolio across multiple therapeutic categories, along with its focus on export markets, make it a consideration for long-term allocations. 

Medico Remedies share price is influenced by the company’s ownership structure. Medico Remedies equity is held by a broad mix of promoters, institutional investors, and retail investors, reflecting its standing in India’s pharmaceutical sector. Promoters hold a stable majority stake of approximately 61.38 percent in the company, reflecting strong internal control, with top promoter shareholders including Haresh Kapurlal Mehta, Rishit Hareshbhai Mehta, and Harshit Haresh Mehta. Foreign institutional investors hold approximately 0.49 percent of the company’s shares, showing an increase from 0.30 percent in the previous quarter, with the number of FII investors decreasing from 4 to 3. Domestic institutional investors hold approximately 0.49 percent of the company’s shares. Mutual funds do not hold any significant stake in the company. The public holds the remaining stake of approximately 38.62 percent in the company. This investor base with stable promoter participation underscores the company’s role as a holding in both domestic and focused portfolios concentrating on pharmaceutical manufacturing. 

Beyond fundamentals and ownership, Medico Remedies stock is actively monitored in cash market segments, where trading volumes and delivery patterns reflect expectations on production levels, export orders, and regulatory policy actions. The stock is available for trading on both the NSE and BSE, allowing investors to take positions based on their outlook for the pharmaceutical sector. Market participants watch these trading indicators to gauge sentiment around quarterly results and policy announcements. 

Technical indicators provide additional insight into short-term momentum shifts in the company’s stock price. While these indicators are primarily used for near-term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements. In the short-term and weekly timeframe, the stock has exhibited price movements that correlate with broader pharmaceutical sector trends. Based on available data, the stock’s return on equity (ROE) stands at approximately 17.6 to 18.57 percent, while return on capital employed (ROCE) stands at approximately 21.7 percent. The company’s debt-to-equity ratio stands at approximately 0.2, indicating manageable financial leverage. The company’s book value per share stands at approximately 8.4 rupees. 

Overall, Medico Remedies demonstrates a relatively stable financial profile with a low beta indicating lower volatility compared to the broader market, making it a relatively lower-risk holding within the pharmaceutical sector. 

Medico Remedies Limited Sectoral Relevance and Peer Positioning 

Medico Remedies Limited sector relevance stems from its three decades of experience in the pharmaceutical formulation manufacturing industry, its comprehensive portfolio covering anti-infectives, beta-lactams (penicillins and cephalosporins), antimalarials, antiretrovirals, anti-ulcer drugs, antacids, vitamins, haematinics, and other therapeutic segments, its export presence across Latin America, Southeast Asia, and Africa, and its manufacturing capabilities for tablets, capsules, ointments, creams, syrups, and dry powder for suspensions, establishing it as a focused small-cap pharmaceutical formulation provider supporting India’s generic drug manufacturing ecosystem. Peer comparisons with companies like Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals, Cipla, Dr. Reddy’s Laboratories, Lupin, Ajanta Pharma, Coral Laboratories, and others focus on manufacturing capabilities, product portfolio, regulatory compliance, and export presence rather than short-term stock moves. These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of pharmaceutical demand, generic drug trends, and regulatory compliance further highlights Medico Remedies positioning within India’s broader pharmaceutical manufacturing market. 

Medico Remedies P/E ratio reflects how investors perceive the company’s earnings relative to its revenue streams from pharmaceutical formulations and nutraceutical sales. Based on available data, the current P/E ratio stands at approximately 27 to 28 times, which is in line with the industry P/E of approximately 29.1 times. The company’s profit after tax increased from approximately 8.29 crore rupees in FY 2024 to approximately 10.09 crore rupees in FY 2025, representing growth of approximately 21.71 percent. In the December 2025 quarter, the company reported a net profit of approximately 2.87 crore rupees, up from 2.62 crore rupees in the corresponding quarter of the previous year. The company’s net profit margin improved from approximately 5.7 percent in FY 2024 to approximately 6.6 percent in FY 2025, reflecting better operational efficiency. Overall, these changes highlight how market sentiment evolved alongside the company’s operational performance in a competitive industry. 

Alongside valuation, Medico Remedies EPS provides insight into its operational performance and income generation from antibiotic, anti-infective, cardiovascular, anti-diabetic, anti-inflammatory, and nutraceutical products. Based on available data, the company reported a basic EPS of approximately 0.31 rupees in the September 2025 quarter, compared to 0.19 rupees in the September 2024 quarter, showing significant growth. The TTM EPS stands at approximately 1.40 rupees. The company’s EPS for FY 2024-25 stood at approximately 1.22 rupees on a basic basis, compared to 1.00 rupees in FY 2023-24. The company has a face value of 2 rupees per share and has not paid any dividends in recent years. More recent quarterly performance suggests that EPS has shown strong growth as the company benefited from higher sales realization and improved operational efficiencies. 

Medico Remedies market cap highlights its position as a small-cap player within India’s pharmaceutical sector. Based on recent data, the company’s market capitalization has fluctuated, standing at approximately 316 to 407 crore rupees depending on the reporting period. The company’s market cap has fluctuated in line with investor perceptions of the company’s growth potential following the significant correction from its highs. From earlier years through more recent periods, the market cap showed a moderate increasing trend as the company expanded its product portfolio and export presence, followed by a significant correction due to broader market volatility and pharmaceutical sector trends. This pattern reflects strong investor confidence during favorable pharmaceutical cycles followed by contraction during challenging periods impacted by increased competition and pricing pressures. This decrease mirrors the correction in the Medico Remedies share price from its 52-week high of approximately 62.48 to recent levels around 37 to 40 rupees per share. 

Finally, Medico Remedies earnings trajectory demonstrates the impact of its operational execution in a competitive industry. In recent fiscal years, total income showed growth supported by the core pharmaceutical business. Based on available data, the company’s revenue increased from approximately 140.44 crore rupees in FY 2023 to approximately 150.94 crore rupees in FY 2025, representing growth of approximately 4.15 percent in the latest fiscal year. The company’s profit after tax increased from approximately 8.29 crore rupees to approximately 10.09 crore rupees over the same period, representing a growth of approximately 21.71 percent. In the December 2025 quarter, the company reported total income of approximately 58.68 crore rupees and net profit of approximately 2.87 crore rupees using revised metric. The company’s operating profit margin has improved to approximately 9.77 percent in FY 2025, while the company’s return on equity stands at approximately 18.57 percent. The company has faced headwinds from fluctuating API prices, increased competitive pressures, and regulatory compliance costs. However, the company continues to expand its manufacturing capabilities, having commenced work for a new factory for manufacturing of B-lactum tablets, capsules, dry syrup, and injections. These developments illustrate the cyclical and competitive nature of the pharmaceutical formulation industry and the company’s position within this sector. 

Summary 

Medico Remedies Limited operates as a pharmaceutical formulation manufacturer producing antibiotics, anti-infectives, and nutraceutical products for domestic and export markets. Medico Remedies share price moves largely with pharmaceutical demand cycles, raw material costs, and broader healthcare sector conditions. Medico Remedies stock price reflects its specific position within the small-cap pharmaceutical manufacturing space. The company’s performance aligns with the operational results of its diversified product portfolio and manufacturing capabilities.